Statistically meaningful improvements in overall survival and disease progression were seen in patients with kidney cancer treated with a combination of Merck's Keytruda, or pembrolizumab, and Pfizer's Inlyta, or axitinib. The combination treatment met the main goals of the late-stage trial as compared with kidney cancer drug Sutent, or sunitinib malate, also from Pfizer.
Keytruda, Inlyta combo shows benefits for kidney cancer patients
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.